Veikko V. Salomaa - Genetic Mutations

Author Information

Veikko V. Salomaa is a prominent researcher affiliated with the National Institute for Health and Welfare in Helsinki, Finland. His extensive work in the field of genetics and public health has significantly contributed to our understanding of various health conditions and their genetic underpinnings.

Research Contributions

Veikko V. Salomaa has made substantial contributions to the field of genetics and epidemiology, particularly focusing on the prediction and analysis of chronic diseases. In 2022, he co-authored several pivotal studies, including the development of models to predict chronic liver disease and type 2 diabetes using gut microbiome composition. His research also explored the genetic variants associated with human height, metabolic aging trends, and the combined effects of genetics and diet on gut microbiota. His work has provided valuable insights into the role of genetics and lifestyle in disease prevention and health behavior.

Aliases

Veikko V. Salomaa is known by various aliases in academic publications, including V Salomaa, Veikko Salomaa, V. V. Salomaa, and other variations of his name. These aliases reflect the common practice of using abbreviated or varied forms of names in scientific literature.

Publication and Citation Metrics

Metric	Value
Citation Count	149,662
h-index	173
Paper Count	1,190

Publications:

Development and validation of a model to predict incident chronic liver disease in the general population: the CLivD score.

DOI: 10.1016/j.jhep.2022.02.021

Year: 2022

Gut Microbiome Composition Is Predictive of Incident Type 2 Diabetes in a Population Cohort of 5,572 Finnish Adults

DOI: 10.2337/figshare.18092744.v1

Year: 2022

A Saturated Map of Common Genetic Variants Associated with Human Height from 5.4 Million Individuals of Diverse Ancestries

DOI: 10.1101/2022.01.07.475305

Year: 2022

Longitudinal profiling of metabolic ageing trends in two population cohorts of young adults.

DOI: 10.1093/ije/dyac062

Year: 2022

Early prediction of incident liver disease using conventional risk factors and gut-microbiome-augmented gradient boosting.

DOI: 10.1016/j.cmet.2022.03.002

Year: 2022

Circulating inflammatory cytokines and risk of five cancers: a Mendelian randomization analysis

DOI: 10.1186/s12916-021-02193-0

Year: 2022

Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort.

DOI: 10.1038/s41588-021-00991-z

Year: 2022

How Communicating Polygenic and Clinical Risk for Atherosclerotic Cardiovascular Disease Impacts Health Behavior: an Observational Follow-up Study

DOI: 10.1161/CIRCGEN.121.003459

Year: 2022

Simple cardiovascular risk stratification by replacing total serum cholesterol with anthropometric measures: The MORGAM prospective cohort project

DOI: 10.1016/j.pmedr.2022.101700

Year: 2022

Gut Microbiome Composition Is Predictive of Incident Type 2 Diabetes in a Population Cohort of 5,572 Finnish Adults

DOI: 10.2337/figshare.18092744

Year: 2022

What is the Genetic Advantage of Sickle Cell Trait?

What Are the Common PARP Inhibitors?

How Are Synonymous Mutations Detected?

Can Mutations Be Treated or Reversed?

What are Viral Vectors?

Why Does Sickle Cell Trait Persist in the Population?

What Are Some Common Developmental Disorders Linked to Genetic Mutations?

How Does Sanger Sequencing Compare to Next-Generation Sequencing (NGS)?

Can Therapies Target Genetic Mutations Caused by Asbestos?

Are There Any Treatments Specifically Targeting BRCA1 and BRCA2 Mutations?

Partnered Content Networks

Relevant Topics